Regulation of Inflammation, Lipid Metabolism, and Liver Fibrosis by Core Genes of M1 Macrophages in NASH

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2024 Dec 3

PMID 39624402

Authors

Xingyu Xu

Yaqin Dong

Jianjun Liu

Peng Zhang

Wenqi Yang

Longfei Dai

Affiliations

Soon will be listed here.

Abstract

Background: Although immune cells play a critical role in lipid metabolism and inflammation regulation in patients with non-alcoholic steatohepatitis (NASH), the specific immune cells involved and associated genes remain unclear.

Methods: We identified differential immune cell profiles between normal liver and NASH specimens using the CIBERSORT algorithm. Next, we conducted a weighted gene co-expression network analysis (WGCNA) to identify genes highly correlated with these immune cells in NASH. Subsequently, core genes of immune cells were identified using machine learning algorithms.

Results: The abundance of M1 macrophages significantly increased in patients with NASH. The Random Forest (RF) algorithm identified six M1 macrophage-related genes (, and ) crucial in NASH. These six genes positively correlated with five inflammatory genes (, and ), lipid synthesis gene (), collagen synthesis genes ( and ), liver fibrosis stage, NASH activity score (NAS), and aspartate aminotransferase (AST) levels. These were negatively correlated with the lipid transport gene (), beta fatty acid oxidation gene (), and M2 macrophage abundance. Moreover, a predictive model based on these six genes achieved a C-index of 0.902 for diagnosing NASH across four cohorts. The expression of these six genes accurately stratified patients with NASH into low disease activity cluster 1 and high disease activity cluster 2.

Conclusion: These six core genes of M1 macrophages contribute to NASH progression by regulating inflammation, lipid metabolism, and liver fibrosis.

References

Lee K, Wu P, Lin H . Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol. 2022; 29(1):77-98. PMC: 9845678. DOI: 10.3350/cmh.2022.0237. View

Younossi Z, Tacke F, Arrese M, Sharma B, Mostafa I, Bugianesi E . Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2018; 69(6):2672-2682. DOI: 10.1002/hep.30251. View

Schuster S, Cabrera D, Arrese M, Feldstein A . Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018; 15(6):349-364. DOI: 10.1038/s41575-018-0009-6. View

Suzuki A, Diehl A . Nonalcoholic Steatohepatitis. Annu Rev Med. 2016; 68:85-98. DOI: 10.1146/annurev-med-051215-031109. View

Dai L, Jiang R, Zhan Z, Zhang L, Qian Y, Xu X . Machine learning-based algorithm identifies key mitochondria-related genes in non-alcoholic steatohepatitis. Lipids Health Dis. 2024; 23(1):137. PMC: 11077862. DOI: 10.1186/s12944-024-02122-z. View

Byrne C, Targher G . NAFLD: a multisystem disease. J Hepatol. 2015; 62(1 Suppl):S47-64. DOI: 10.1016/j.jhep.2014.12.012. View

Liu B, Deng X, Jiang Q, Li G, Zhang J, Zhang N . Scoparone improves hepatic inflammation and autophagy in mice with nonalcoholic steatohepatitis by regulating the ROS/P38/Nrf2 axis and PI3K/AKT/mTOR pathway in macrophages. Biomed Pharmacother. 2020; 125:109895. DOI: 10.1016/j.biopha.2020.109895. View

Kazankov K, Jorgensen S, Thomsen K, Moller H, Vilstrup H, George J . The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2018; 16(3):145-159. DOI: 10.1038/s41575-018-0082-x. View

Langfelder P, Horvath S . WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008; 9:559. PMC: 2631488. DOI: 10.1186/1471-2105-9-559. View

10.

Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A . Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 2013; 14(11):22933-66. PMC: 3856099. DOI: 10.3390/ijms141122933. View

11.

Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi A, Tanaseichuk O . Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019; 10(1):1523. PMC: 6447622. DOI: 10.1038/s41467-019-09234-6. View

12.

Stefan N, Cusi K . A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022; 10(4):284-296. DOI: 10.1016/S2213-8587(22)00003-1. View

13.

Ye Q, Zou B, Yeo Y, Li J, Huang D, Wu Y . Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(8):739-752. DOI: 10.1016/S2468-1253(20)30077-7. View

14.

Polyzos S, Kountouras J, Mantzoros C . Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2018; 92:82-97. DOI: 10.1016/j.metabol.2018.11.014. View

15.

Lee Y, Jang H, Kim S, Choi S, Khim K, Eom H . Hepatic promotes nonalcoholic fatty liver disease by suppressing . Elife. 2021; 10. PMC: 8758141. DOI: 10.7554/eLife.70472. View

16.

Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, Bader G . GeneMANIA update 2018. Nucleic Acids Res. 2018; 46(W1):W60-W64. PMC: 6030815. DOI: 10.1093/nar/gky311. View

17.

Yan L, Zhang S, Luo G, Chi-Yan Cheng B, Zhang C, Wang Y . Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway. Metabolism. 2022; 131:155200. DOI: 10.1016/j.metabol.2022.155200. View

18.

Guo Y, Yu J, Wang C, Li K, Liu B, Du Y . miR-212-5p suppresses lipid accumulation by targeting FAS and SCD1. J Mol Endocrinol. 2017; 59(3):205-217. DOI: 10.1530/JME-16-0179. View

19.

Tsuchida T, Friedman S . Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017; 14(7):397-411. DOI: 10.1038/nrgastro.2017.38. View

20.

Castera L, Friedrich-Rust M, Loomba R . Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019; 156(5):1264-1281.e4. PMC: 7505052. DOI: 10.1053/j.gastro.2018.12.036. View